Cantor Fitzgerald’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

Cantor Fitzgerald’s Portfolio ORIA Stock Details ORIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-589,286	Closed	-$6.03M	–	752
2023 Q1	$6.03M	Buy	589,286 +300	+0.1%	+$3.05K	0.13%	221
2022 Q4	$5.92M	Sell	588,986 -100,300	-15%	-$999K	0.13%	220
2022 Q3	$6.79M	Hold	689,286	–	–	0.15%	194
2022 Q2	$6.71M	Buy	689,286 +200,000	+41%	+$1.95M	0.13%	204
2022 Q1	$4.77M	Buy	+489,286	New	+$4.75M	0.36%	84

Cantor Fitzgerald's ORIA Position: Q2 2023 in Review

Cantor Fitzgerald sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q2 2023, closing a stake of 589,286 shares — an estimated $6.03M sold.

Cantor Fitzgerald first reported a position in ORIA in Q1 2022 and held it in 5 quarters. The position peaked at $6.79M in Q3 2022. 0 funds tracked by Wall St. Rank hold ORIA as of Q2 2023.

Cantor Fitzgerald reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q2 2023 after selling out during the quarter.
Cantor Fitzgerald sold 589,286 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q2 2023, an estimated $6.03M.
Cantor Fitzgerald first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q1 2022 and held it in 5 quarters.
Cantor Fitzgerald's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $6.79M in Q3 2022.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q2 2023.

Based on Cantor Fitzgerald's 13F filing for Q2 2023, filed 14 Aug 2023.